Aclaris Therapeutics, Inc.
ACRS
$3.59
$0.298.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -60.75% | 85.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.75% | 85.65% | |||
| Cost of Revenue | 46.82% | 9.13% | |||
| Gross Profit | -78.46% | 2.67% | |||
| SG&A Expenses | 14.47% | -9.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.12% | 8.90% | |||
| Operating Income | -31.00% | -0.83% | |||
| Income Before Tax | -35.45% | 5.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.45% | 5.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.45% | 5.28% | |||
| EBIT | -31.00% | -0.83% | |||
| EBITDA | -31.02% | -0.94% | |||
| EPS Basic | -35.40% | 5.32% | |||
| Normalized Basic EPS | -33.51% | -4.23% | |||
| EPS Diluted | -35.40% | 5.32% | |||
| Normalized Diluted EPS | -33.51% | -4.23% | |||
| Average Basic Shares Outstanding | 0.04% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.04% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||